In a Push to Limit Use of Glucocorticoids, US and EU5 Rheumatologists are Increasingly Turning ...

Exton, Pennsylvania, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Prior to the initial approval of Benlysta in 2011, systemic lupus erythematosus (SLE) patients and prescribers had limited options for the management

Related Keywords

Pennsylvania ,United States ,Aurinia Lupkynis ,Astrazeneca Saphnelo ,Maxine Yarnall Spherix ,European Union ,Astrazeneca ,Spherix Network ,Linkedin ,Twitter ,Global Insights ,Patient Chart Dynamix ,Realworld Dynamix ,Chart Dynamix ,Spherix Global Insights ,Spherix Global Insight ,Yarnall Spherix Global Insights ,Systemic Lupus Erythematosus ,Sale ,Benlysta ,Lucorticiods ,Lupus Nephritis ,Heumatology ,Aurinia ,Lupkynis ,Wular ,Aphnelo ,Kidney Disease ,Skin Conditions ,Lupus ,Health ,